In a report released on January 27, Greg Harrison from Bank of America Securities reiterated a Buy rating on Senti Biosciences (SNTI – Research Report), with a price target of $6.00. The company’s shares closed last Friday at $1.78.
According to TipRanks, Harrison is a 4-star analyst with an average return of 11.9% and a 55.56% success rate. Harrison covers the Healthcare sector, focusing on stocks such as Stoke Therapeutics, Omeros, and Sangamo Biosciences.
In addition to Bank of America Securities, Senti Biosciences also received a Buy from Chardan Capital’s Geulah Livshits in a report issued on January 27. However, on the same day, Morgan Stanley maintained a Hold rating on Senti Biosciences (NASDAQ: SNTI).
See the top stocks recommended by analysts >>
Based on Senti Biosciences’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $1.52 million and a GAAP net loss of $16.64 million. In comparison, last year the company earned a revenue of $778 thousand and had a GAAP net loss of $12.01 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Dynamics Special Purpose Corp is a blank check company.
Read More on SNTI:
- Senti Bio price target lowered to $8 from $12 at Chardan
- Senti Bio sees cash runway through at least 1Q24
- Senti Bio does not intend to invest in development of SENTI-301A
- Senti Bio to focus resources on SENTI-202, SENTI-401
- Senti Bio Announces Pipeline Prioritization to Focus on Logic Gated Cell Therapies; Updates Cash Runway Guidance
